Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSToday, there are approximately 350 million people living with 7,000 rare diseases worldwide. In the United States alone, 25 to 30 million people are affected – more than half of whom are children – while treatments are available for just 5% of them. As these diseases are exceedingly rare, initial misdiagnosis is common and underdiagnosis is extensive. On average, it can take more than seven years for patients with a rare disease to receive an accurate diagnosis – which creates a significant delay to critical treatment options for these patients.
We must find a more reliable means of detecting rare diseases to ensure patients get the treatments they need. With advances in machine learning and deep learning technologies, we can now begin to pursue answers to questions about these diseases regardless of the complexity in faster, more compelling ways.
Two primary challenges exist in using machine learning to detect rare diseases. First, the low prevalence rates of these diseases limit the number of positive subjects in the training data (i.e., patients with a confirmed diagnosis of a disease). Thus, disease patterns are hard to extract.
This is made more difficult by the fact that many rare diseases have not been assigned an ICD-10 code. ICD-10 codes are used by physicians to identify specific diseases or symptoms. In the case of many rare diseases, each physician must use their judgment to select an ICD-10 code that best accounts for a patient’s symptoms. In practice, this means a set of patients who in fact share the same disease could each be assigned a different ICD-10 code.
Second, there are many patients with an uncertain diagnosis due to the long period needed for rare diseases to be correctly diagnosed. Although we do not know who those patients are, their existence can potentially help. In recent years, the availability of massive electronic health records (EHR) data has further enabled the training of deep learning models for accurate predictive health.
While artificial intelligence holds great promise for detecting undiagnosed patients, the barrier is much higher with rare diseases due to the difficulty in distinguishing between patients with similar conditions due to the low prevalence rates of rare diseases. To tackle these challenges, we need to continue to evolve how we apply machine learning. One way is to use pattern augmentation to better preserve and enrich crucial patterns of the target disease.
In partnership with Jimeng Sun, University of Illinois Urbana-Champaign, my team at IQVIA published a paper featured at AAAI 2020 outlining a Complementary Pattern Augmentation (CONAN) framework for rare and low prevalence disease detection.
CONAN uses the idea of adversarial learning. First, a generator learns to create plausible, but fake, patient samples. Then, a disease detector aims to distinguish between negative and positive patient samples. This establishes what is called a minimax game between the generator and disease detector. After this training, the disease detector can be used for detecting positive patients. Experiments on real-world data sets demonstrated strong performance. Read the full paper here.
Improving the ability to detect rare diseases is a critical step in finding answers to the perplexing questions surrounding rare diseases, and ultimately ensuring patients can be properly diagnosed and treated. To build on this success, deep expertise and creativity are required to challenge the way things have been done previously and to make connections, with accuracy, even when it seems impossible.
At IQVIA, we believe the pursuit of a healthier world begins by solving problems that once seemed unsolvable and enabling treatments for diseases once thought untreatable. In this pursuit, Human Data Science leads the way. It’s a revolutionary way to approach problem solving in healthcare, harnessing advances in technology, data science and human ingenuity to improve human health.
For more information on rare diseases and orphan drugs read the IQVIA Institute report.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.